Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas
Condition: Vitiligo Interventions: Drug: Ruxolitinib Topical; Drug: Placebo Sponsor: Centre Hospitalier Universitaire de Nice Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 24, 2023 Category: Research Source Type: clinical trials
